Login Register Cart 0
Generic placeholder image

Current Pediatric Reviews

Editor-in-Chief

ISSN (Print): 1573-3963
ISSN (Online): 1875-6336

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Testing an Ectoin Containing Emollient for Atopic Dermatitis

Author(s): Kam Lun Hon*, Jeng Sum Kung, Wing Gi Gigi Ng and Ting Fan Leung

Volume 15, Issue 3, 2019

Page: [191 - 195] Pages: 5

DOI: 10.2174/1573396315666190415144244

Abstract

Aim: To describe the methodology in studying patient’s acceptability and efficacy of an ectoin containing emollient for atopic dermatitis (AD).

Methods: We described the methodology that we used in studying emollients and moisturisers, and patient acceptability of a group of AD patients before and following usage of an ectoin-containing proprietary emollient. These data were also compared with other brand emollients that we previously reported, namely Restoradom®, Ezerra® and Ezerra plus®.

Results: 30 subjects (50% Male, Mean (SD) age: 9.8 (3.6) years with AD used the trial emollient W for four weeks. AD severity of subjects (by objective SCORAD) was moderate (n=22) and severe (n=8). Compliance was good and patients generally managed to use the moisturisers daily, with individual reports of a ‘tingly’ sensation by some subjects when applied to inflamed wounds. 63% reported “very good” or “good”, whereas 37% reported “fair” or “poor” acceptability of the moisturisers. Following use of the trial emollient, area affected, disease intensity and severity significantly improved, as demonstrated in objective SCORAD (p=0.002). There were also significant improvements in POEM (p=0.035), and PADQLQ scores (p=0.017). For skin measurements, only transepidermal water loss had improved (p=0.035) after the treatment. There was no significant improvement of itch or sleep scores, skin hydration, pH, S. aureus colonization status, or need for use of topical medications. When compared with historical data of other emollients, the mean age of patients on emollient W was younger; efficacy and acceptability among these emollients were similar.

Conclusion: Methodology of emollient research is described. Doctors should provide evidencebased information about the efficacy of emollients. The ectoin-containing proprietary emollient improves disease and quality of life following its use in 4 weeks. Efficacy and acceptability are similar among 4 proprietary emollients.

Keywords: Ectoin, eczema, emollient, transepidermal water loss, skin hydration, Restoradom®, Ezerra®.

« Previous
[1]
Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr 2007; 54: 241-73.
[http://dx.doi.org/10.1016/j.yapd.2007.03.013] [PMID: 17918474]
[2]
Leung TN, Hon KL. Eczema therapeutics in children: what do the clinical trials say? Hong Kong Med J 2015; 21(3): 251-60.
[http://dx.doi.org/10.12809/hkmj144474] [PMID: 25904389]
[3]
van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen A, Arents BWM. Emollients and moisturisers for eczema Cochrane Database Syst Rev 2017; 2CD012119
[PMID: 28166390]
[4]
Giam YC, Hebert AA, Dizon MV, et al. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy 2016; 6(2): 120-8.
[http://dx.doi.org/10.5415/apallergy.2016.6.2.120] [PMID: 27141486]
[5]
Hon KL, Leung AK, Barankin B. Barrier repair therapy in atopic dermatitis: an overview. Am J Clin Dermatol 2013; 14(5): 389-99.
[http://dx.doi.org/10.1007/s40257-013-0033-9] [PMID: 23757122]
[6]
Hon KL, Tsang YC, Pong NH, et al. Patient acceptability, efficacy, and skin biophysiology of a cream and cleanser containing lipid complex with shea butter extract versus a ceramide product for eczema. Hong Kong Med J 2015; 21(5): 417-25.
[http://dx.doi.org/10.12809/hkmj144472] [PMID: 26314567]
[7]
Hon KL, Wang SS, Pong NH, Leung TF. The ideal moisturizer: a survey of parental expectations and practice in childhood-onset eczema. J Dermatolog Treat 2013; 24(1): 7-12.
[http://dx.doi.org/10.3109/09546634.2012.672713] [PMID: 22390400]
[8]
Hon KL, Kung JSC, Tsang KYC, Yu JWS, Lee VW, Leung TF. Emollient acceptability in childhood atopic dermatitis: Not all emollients are equal? Curr Pediatr Rev 2018; 14(2): 117-22.
[http://dx.doi.org/10.2174/1573396313666170605080034] [PMID: 28578641]
[9]
Hon KL, Leung AK. Use of ceramides and related products for childhood-onset eczema. Recent Pat Inflamm Allergy Drug Discov 2013; 7(1): 12-9.
[http://dx.doi.org/10.2174/187221313804004673] [PMID: 23083072]
[10]
Hon KL, Pong NH, Wang SS, Lee VW, Luk NM, Leung TF. Acceptability and efficacy of an emollient containing ceramide-precursor lipids and moisturizing factors for atopic dermatitis in pediatric patients. Drugs R D 2013; 13(1): 37-42.
[http://dx.doi.org/10.1007/s40268-013-0004-x] [PMID: 23456759]
[11]
Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131(3): 406-16.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb08532.x] [PMID: 7918017]
[12]
Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994; 131(3): 397-405.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb08531.x] [PMID: 7918016]
[13]
Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131(3): 383-96.
[http://dx.doi.org/10.1111/j.1365-2133.1994.tb08530.x] [PMID: 7918015]
[14]
Hon KL, Wong KY, Leung TF, Chow CM, Ng PC. Comparison of skin hydration evaluation sites and correlations among skin hydration, transepidermal water loss, SCORAD index, Nottingham Eczema Severity Score, and quality of life in patients with atopic dermatitis. Am J Clin Dermatol 2008; 9(1): 45-50.
[http://dx.doi.org/10.2165/00128071-200809010-00005] [PMID: 18092843]
[15]
Stalder JF, Taïeb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 1993; 186(1): 23-31.
[http://dx.doi.org/10.1159/000247298] [PMID: 8435513]
[16]
Chuh AA. Validation of a Cantonese version of the Children’s Dermatology Life Quality Index. Pediatr Dermatol 2003; 20(6): 479-81.
[http://dx.doi.org/10.1111/j.1525-1470.2003.20604.x] [PMID: 14651564]
[17]
Hon KL, Kam WY, Lam MC, Leung TF, Ng PC. CDLQI, SCORAD and NESS: are they correlated? Qual Life Res 2006; 15(10): 1551-8.
[http://dx.doi.org/10.1007/s11136-006-0019-7] [PMID: 16826438]
[18]
Ng DK, Wong KC, Chan CH, Ng EP. Development of the Chinese version of the Paediatric Allergic Disease Quality of Life Questionnaire: reliability and validity. Hong Kong Med J 2011; 17(6): 460-4.
[PMID: 22147315]
[19]
Hon KL, Kung JSC, Tsang KY, Yu JW, Wong N, Leung TF. Do we need another symptom score for childhood eczema? J Dermatolog Treat 2018; 29(5): 510-4. 10.1080/09546634.2017.1373734
[PMID: 28849683]
[20]
Graf R, Anzali S, Buenger J, Pfluecker F, Driller H. The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 2008; 26(4): 326-33.
[http://dx.doi.org/10.1016/j.clindermatol.2008.01.002] [PMID: 18691511]
[21]
Leung TNH, Chow CM, Chow MPY, et al. Clinical guidelines on management of atopic dermatitis in children. Hong Kong J Paediatr 2013; 18: 96-104.
[22]
Leung A, Hon K. Atopic dermatitis: a review for the primary care physician A review for the primary care physician Atopic Dermatitis: A Rev Primary Care Physic 2011; 1-113
[23]
Marini A, Reinelt K, Krutmann J, Bilstein A. Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: a randomised, comparator-controlled, intra-individual double-blind, multi-center trial. Skin Pharmacol Physiol 2014; 27(2): 57-65.
[http://dx.doi.org/10.1159/000351381] [PMID: 23949258]
[24]
Warshaw EM, Zug KA, Belsito DV, et al. Positive Patch-Test Reactions to Essential Oils in Consecutive Patients From North America and Central Europe. Dermatitis 2017; 28(4): 246-52.
[http://dx.doi.org/10.1097/DER.0000000000000293] [PMID: 28614106]
[25]
van Zuuren EJ, Fedorowicz Z, Arents BWM. Performance and Tolerability of the Moisturizers Cetaphil® and Excipial® in Atopic Dermatitis: What is the Evidence Based on Randomized Trials? Dermatol Ther (Heidelb) 2017; 7(3): 331-47.
[http://dx.doi.org/10.1007/s13555-017-0184-3] [PMID: 28600606]

Rights & Permissions Print Cite
Article Metrics
29
8
1
1
© 2024 Bentham Science Publishers | Privacy Policy